Eisai Co., Ltd., Epizyme, Inc. and Roche Holding AG announced a collaboration to develop an in vitro PCR (Polymerase Chain Reaction) based companion diagnostic test. The collaboration's goal is to identify lymphoma patients with non-wild type EZH2, including the Y641 mutation. Eisai and Epizyme are collaborating to develop an EZH2 inhibitor as a personalized therapeutic for patients with genetically defined cancers.
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
6,958 JPY | +0.46% | +7.41% | 12.6B | ||
254.8 CHF | +1.07% | +4.73% | 230B | ||
1st Jan change | Capi. | |
---|---|---|
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |